Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

This study is investigating the effectiveness (specifically the objective response rate - ORR) of a new combination therapy called CAMP (chidamide, azacitidine, liposomal mitoxantrone, and prednisone) for previously untreated angioimmunoblastic T-cell lymphoma (AITL). It's a single-arm study comparing CAMP's safety and efficacy to standard treatments. Younger patients (≤70) receive the full CAMP regimen, while older patients receive a modified version (CAMP-light). Patients are assessed via PET-CT after 4 cycles. Responders (CR/PR) receive consolidation therapy and then maintenance chidamide f

Trial Details

NCT ID

NCT05958719

Phase

PHASE2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

Chidamide
Azacitidine
liposomal mitoxantrone
prednisone

Locations (sample)

Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

Subjects must have histological confirmation of nodal T-follicular helper (TFH) cell lymphoma.
More than 18 years of age.
Proper functioning of the major organs: 1) The absolute value of neutrophils (≥1×10\^9/L); 2) platelet count (≥75×10\^9/L); 3) Serum total bilirubi…
Eastern Cooperative Oncology Group (ECOG) Performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →